Xerys leads €14m series-B for AlzProtect

As a result of the latest funding round, Xerys is now the main financial investor in the company. Other historical investors also took part in the funding round.

With the fresh capital, AlzProtect intends to develop an oral drug for the treatment of progressive supranuclear palsy, a condition in a group of neurodegenerative diseases that include Alzheimer's disease and Parkinson's disease.

Company
Founded in 2007 and headquartered in Loos, northern France, AlzProtect develops new bioactive molecules for the treatment of neurodegenerative diseases up to the first clinical trial in patients.

It also partners with pharmaceutical companies for further development and marketing.

People
Xerys Gestion – Olivier Ossipoff (president).
AlzProtect – Laurent Dupire (CEO). 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• Venture